The Food and Drug Administration (FDA) has launched a pilot program designed to accelerate the domestic manufacturing of critical medicines and bolster American jobs. The PreCheck Pilot Program aims to streamline regulatory processes for new pharmaceutical manufacturing facilities in the United States, addressing long-standing concerns about reliance on foreign supply chains.
For decades, a significant portion of prescription medications filled in the U.S. have been manufactured in facilities located outside the country. Regulatory hurdles, including lengthy post-construction reviews that could take up to 14 months, have historically discouraged domestic investment in pharmaceutical production. This has contributed to vulnerabilities in the medicine supply chain and limited high-paying employment opportunities for American workers.
Executive Order 14293, signed by President Donald Trump, directed the FDA to reduce regulatory obstacles and incentivize domestic production. The PreCheck program is presented as a direct response to this directive, intended to foster a resurgence in U.S.-based manufacturing.
The program operates in two phases. The initial Facility Readiness Phase provides manufacturers with early technical and regulatory feedback before operations commence, aiming to prevent costly compliance errors. The subsequent Application Submission Phase involves enhanced FDA engagement to expedite the resolution of manufacturing questions, accelerate the review of facility information, and fast-track inspections.
By identifying and addressing potential issues early, the PreCheck program seeks to improve regulatory predictability and shorten the time it takes for U.S.-manufactured medicines to become available. This initiative is intended to ensure that medical innovations are developed and produced domestically.
Seven companies have been selected as initial participants in the PreCheck program: Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. These companies are currently developing or scaling up operations for a range of products, from advanced cell and gene therapies to essential IV bags. The FDA estimates that these participants alone could create thousands of long-term, high-wage jobs for scientists, engineers, technicians, and operators, while also generating additional employment across various sectors.
In addition to the PreCheck pilot, the FDA is also moving forward with draft regulations to simplify pathways for distributed manufacturing and increase transparency regarding foreign medicine suppliers. The agency is also prioritizing applications for older, generic medicines that utilize domestic supply chains, as these drugs represent a significant portion of U.S. prescriptions but are frequently manufactured overseas.
This effort to onshore pharmaceutical production is part of a broader initiative to secure the nation's health, national security, and economic prosperity by strengthening domestic manufacturing capabilities and reducing reliance on foreign sources for essential goods. The FDA views itself as a catalyst for this domestic growth, aiming to protect patients, stimulate economic activity, and enhance American independence.